STAT

This biotech aims to transform the diagnosis of mental illness. Michael Phelps backs it. Can it really work?

A small Australian biotech has backing from Michael Phelps. Its bold goal: to develop an objective way to diagnose mental illnesses. Can it possibly work?
Swimming superstar Michael Phelps serves on the board of Medibio, which is developing a quick, cheap, and objective way to diagnose an array of mental illnesses.

A small Australian biotech has drawn big-name backers — including swimming superstar Michael Phelps — to its audacious goal: to develop a quick, cheap, and objective way to diagnose an array of mental illnesses.

The tool would be a stunning breakthrough in the field of mental health —  if it works.

And there’s the rub. Researchers have been trying for decades to find reliable biomarkers for mental illness — that is, tangible biological clues that conclusively indicate whether a person has a particular psychiatric disease. Effort after effort has failed, leaving doctors to diagnose such conditions mostly on the basis of screening checklists and conversations with their patients.

Now, Medibio — a public company that trades on the Australian stock exchange at less than 30 U.S. cents per share — says it’s developed an algorithm based on hundreds of biomarkers related to a patient’s sleep, heart rate,

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About A GLP-1 Side Effect, U.K. Clinical Trial Transparency, And More
A new study links GLP-1 drugs like Ozempic to a higher risk of aspiration pneumonia — a lung infection caused by food breathed into the lungs — after endoscopies.
STAT1 min read
STAT+: Medicare Expected To Negotiate Obesity Drug Prices Soon, New Analysis Predicts
Medicare will likely choose the obesity drug semaglutide for price negotiation “within the next few years,” according to a new analysis.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About An AstraZeneca Deal, A WHO Pandemic Pact, And More
AstraZeneca agreed to acquire Fusion Pharmaceuticals in a deal worth more than $2 billion, picking up a company focused on targeted radiation therapies for cancer.

Related Books & Audiobooks